| Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study P Münster, D Marchion, E Bicaku, M Schmitt, JH Lee, R DeConti, ... Journal of Clinical Oncology 25 (15), 1979-1985, 2007 | 267 | 2007 |
| Valproic acid alters chromatin structure by regulation of chromatin modulation proteins DC Marchion, E Bicaku, AI Daud, DM Sullivan, PN Munster Cancer research 65 (9), 3815-3822, 2005 | 249 | 2005 |
| ABCG2 expression, function, and promoter methylation in human multiple myeloma JG Turner, JL Gump, C Zhang, JM Cook, D Marchion, L Hazlehurst, ... Blood 108 (12), 3881-3889, 2006 | 243 | 2006 |
| Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway PN Münster, DC Marchion, AD Basso, N Rosen Cancer research 62 (11), 3132-3137, 2002 | 214 | 2002 |
| Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid DC Marchion, E Bicaku, AI Daud, V Richon, DM Sullivan, PN Munster Journal of cellular biochemistry 92 (2), 223-237, 2004 | 208 | 2004 |
| Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker PN Munster, D Marchion, S Thomas, M Egorin, S Minton, G Springett, ... British journal of cancer 101 (7), 1044-1050, 2009 | 191 | 2009 |
| Development of histone deacetylase inhibitors for cancer treatment D Marchion, P Münster Expert review of anticancer therapy 7 (4), 583-598, 2007 | 188 | 2007 |
| Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC P Munster, D Marchion, E Bicaku, M Lacevic, J Kim, B Centeno, A Daud, ... Clinical cancer research 15 (7), 2488-2496, 2009 | 176 | 2009 |
| IgA transcytosis and antigen recognition govern ovarian cancer immunity S Biswas, G Mandal, KK Payne, CM Anadon, CD Gatenbee, RA Chaurio, ... Nature 591 (7850), 464-470, 2021 | 134 | 2021 |
| Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy S Thomas, KT Thurn, E Biçaku, DC Marchion, PN Münster Breast cancer research and treatment 130, 437-447, 2011 | 120 | 2011 |
| Selective inhibition of histone deacetylase 2 silences progesterone receptor–mediated signaling E Biçaku, DC Marchion, ML Schmitt, PN Münster Cancer research 68 (5), 1513-1519, 2008 | 115 | 2008 |
| Metabolic vulnerabilities in endometrial cancer FL Byrne, IKH Poon, SC Modesitt, JL Tomsig, JDY Chow, ME Healy, ... Cancer research 74 (20), 5832-5845, 2014 | 113 | 2014 |
| BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival DC Marchion, HM Cottrill, Y Xiong, N Chen, E Bicaku, WJ Fulp, N Bansal, ... Clinical Cancer Research 17 (19), 6356-6366, 2011 | 110 | 2011 |
| ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression Y Cao, J Trillo-Tinoco, RA Sierra, C Anadon, W Dai, E Mohamed, L Cen, ... Nature communications 10 (1), 1280, 2019 | 106 | 2019 |
| Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial AI Daud, J Dawson, RC DeConti, E Bicaku, D Marchion, S Bastien, ... Clinical Cancer Research 15 (7), 2479-2487, 2009 | 106 | 2009 |
| BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells KK Payne, JA Mine, S Biswas, RA Chaurio, A Perales-Puchalt, ... Science 369 (6506), 942-949, 2020 | 104 | 2020 |
| In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates DC Marchion, E Bicaku, AI Daud, DM Sullivan, PN Munster Molecular cancer therapeutics 4 (12), 1993-2000, 2005 | 103 | 2005 |
| Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition JG Turner, DC Marchion, JL Dawson, MF Emmons, LA Hazlehurst, ... Cancer research 69 (17), 6899-6905, 2009 | 92 | 2009 |
| Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells CM Anadon, X Yu, K Hänggi, S Biswas, RA Chaurio, A Martin, KK Payne, ... Cancer Cell 40 (5), 545-557. e13, 2022 | 73 | 2022 |
| Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ DC Marchion, E Bicaku, JG Turner, AI Daud, DM Sullivan, PN Munster Clinical cancer research 11 (23), 8467-8475, 2005 | 73 | 2005 |
